Phase 1 Alzheimer's Disease Trial, Recruiting (NCT03809351)

Phase 1 Alzheimer's Disease Trial, Recruiting NCT03809351 Sponsor: University of Alabama at Birmingham Condition: Alzheimer's Disease

Printed from Voxsanity (voxsanity.com.au) — NCT03809351 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Alzheimers Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are already enrolled in the UAB Alzheimer's Disease Center (UAB-ADC) study through a separately approved research program.
People who are already enrolled in the UAB-ADC amyloid brain scan (amyloid-PET) sub-study through a separately approved research program. The amyloid brain scan does not need to be finished before joining this study.
Women who could potentially be pregnant must have a negative pregnancy test (urine or blood) within 2 days of receiving the study scan injection. Women who have not had a period for at least 1 year, or who have had a documented surgical procedure to prevent pregnancy, do not need a pregnancy test.

Who may not be able to join:

People who do not meet the eligibility requirements of the UAB-ADC study.
People for whom MRI or PET brain scans are not safe or not possible for any reason.
People whose dementia is at a stage of severity that would prevent them from being able to participate in the brain scanning procedures.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (205) 934-4501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03809351

Sponsor: University of Alabama at Birmingham

Phase: Phase 1

Status: Recruiting

Condition: Alzheimer's Disease

Trial contact: (205) 934-4501

More information: https://clinicaltrials.gov/study/NCT03809351

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are already enrolled in the UAB Alzheimer's Disease Center (UAB-ADC) study through a separately approved research program.
People who are already enrolled in the UAB-ADC amyloid brain scan (amyloid-PET) sub-study through a separately approved research program. The amyloid brain scan does not need to be finished before joining this study.
Women who could potentially be pregnant must have a negative pregnancy test (urine or blood) within 2 days of receiving the study scan injection. Women who have not had a period for at least 1 year, or who have had a documented surgical procedure to prevent pregnancy, do not need a pregnancy test.

Who may not be able to join:

People who do not meet the eligibility requirements of the UAB-ADC study.
People for whom MRI or PET brain scans are not safe or not possible for any reason.
People whose dementia is at a stage of severity that would prevent them from being able to participate in the brain scanning procedures.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

University of Alabama at Birmingham

Registry

ClinicalTrials.gov

Start date

8 July 2020

Est. completion

1 July 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Measurement of pathological tau deposition in the brain.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov